Anebulo Pharmaceuticals (ANEB) Projected to Post Quarterly Earnings on Wednesday

Anebulo Pharmaceuticals (NASDAQ:ANEB) is projected to post its Q4 2025 results before the market opens on Wednesday, September 24th. Analysts expect Anebulo Pharmaceuticals to post earnings of ($0.05) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Monday, September 22, 2025 at 4:00 PM ET.

Anebulo Pharmaceuticals Price Performance

Anebulo Pharmaceuticals stock opened at $2.49 on Wednesday. The stock has a market capitalization of $102.29 million, a PE ratio of -9.58 and a beta of -0.89. Anebulo Pharmaceuticals has a 12 month low of $0.80 and a 12 month high of $3.42. The business has a 50 day simple moving average of $2.40 and a 200-day simple moving average of $1.64.

Analysts Set New Price Targets

Separately, Maxim Group cut Anebulo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals at the end of the most recent quarter. 28.40% of the stock is currently owned by hedge funds and other institutional investors.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.